Skip navigation
Skip navigation

Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer

Snyder, Raymond; Boyle, Frances; Chan, Arlene; Craft, Paul; De Boer, Richard; Mainwaring, Paul; McCarthy, Nicole; Wilcken, Nick

Description

Primary and acquired resistance to trastuzumab pose a therapeutic challenge when treating patients with HER2 (erbB-2)-positive locally advanced or metastatic breast cancer (MBC). The recent introduction of lapatinib (Tykerb/Tyverb, GlaxoSmithKline, Brentford, UK) provides a new management option for such patients. A prospective, randomized phase III clinical trial has confirmed that lapatinib in combination with capecitabine extends time to progressive disease in HER2-positive MBC, compared...[Show more]

dc.contributor.authorSnyder, Raymond
dc.contributor.authorBoyle, Frances
dc.contributor.authorChan, Arlene
dc.contributor.authorCraft, Paul
dc.contributor.authorDe Boer, Richard
dc.contributor.authorMainwaring, Paul
dc.contributor.authorMcCarthy, Nicole
dc.contributor.authorWilcken, Nick
dc.date.accessioned2015-12-10T21:56:14Z
dc.identifier.issn1743-7563
dc.identifier.urihttp://hdl.handle.net/1885/39329
dc.description.abstractPrimary and acquired resistance to trastuzumab pose a therapeutic challenge when treating patients with HER2 (erbB-2)-positive locally advanced or metastatic breast cancer (MBC). The recent introduction of lapatinib (Tykerb/Tyverb, GlaxoSmithKline, Brentford, UK) provides a new management option for such patients. A prospective, randomized phase III clinical trial has confirmed that lapatinib in combination with capecitabine extends time to progressive disease in HER2-positive MBC, compared with capecitabine alone in patients with disease progression despite prior anthracycline, taxane and trastuzumab therapy. Preliminary data also indicate that lapatinib may exert a beneficial effect on brain metastases, a common sanctuary site for HER2-positive breast cancer following trastuzumab treatment. The tolerability of lapatinib is commensurate with that of other erbB family tyrosine kinase inhibitors and no significant new adverse events have emerged following its introduction into clinical practice. In particular, no additive cardiotoxicity has been observed when lapatinib is prescribed after trastuzumab therapy. Based on the published literature and supplemented by clinical experience, this article provides practical management recommendations for the use of lapatinib plus capecitabine in patients with MBC. Issues addressed include patient selection, baseline evaluation and monitoring for clinical benefit. The minimization and management of adverse events is also discussed in detail, particularly the dermatological and gastrointestinal effects, which are the most clinically significant side-effects of lapatinib therapy. Further recommendations cover the minimization of drug interactions, anticipated dosing alterations and the optimal employment of oral anticancer regimens.
dc.publisherBlackwell Publishing Ltd
dc.sourceAsia-Pacific Journal of Clinical Oncology
dc.subjectKeywords: anthracycline; bisphosphonic acid derivative; capecitabine; carbamazepine; clarithromycin; cortisone; cytochrome P450 3A4; dexamethasone; efavirenz; epidermal growth factor receptor 2; epidermal growth factor receptor kinase inhibitor; fosphenytoin sodium Breast neoplasm; Epidermal growth factor receptor (EGFR); ErbB-2receptor (HER2); Lapatinib; Medication therapy management
dc.titleClinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer
dc.typeJournal article
local.description.notesImported from ARIES
local.identifier.citationvolume5
dc.date.issued2009
local.identifier.absfor111205 - Chemotherapy
local.identifier.ariespublicationu4201517xPUB175
local.type.statusPublished Version
local.contributor.affiliationSnyder, Raymond, St Vincent's Hospital
local.contributor.affiliationBoyle, Frances, Mater Hospital
local.contributor.affiliationChan, Arlene, Mount Hospital
local.contributor.affiliationCraft, Paul, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationDe Boer, Richard, Royal Melbourne Hospital
local.contributor.affiliationMainwaring, Paul, Mater Adult Hospital
local.contributor.affiliationMcCarthy, Nicole, Royal Brisbane and Women's Hospital
local.contributor.affiliationWilcken, Nick, Westmead Hospital
local.description.embargo2037-12-31
local.bibliographicCitation.startpage4
local.bibliographicCitation.lastpage16
local.identifier.doi10.1111/j.1743-7563.2009.01194.x
dc.date.updated2016-02-24T10:40:58Z
local.identifier.scopusID2-s2.0-61649091368
CollectionsANU Research Publications

Download

File Description SizeFormat Image
01_Snyder_Clinical_recommendations_for_2009.pdf454.35 kBAdobe PDFThumbnail


Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  19 May 2020/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator